Brilinta instructions for use
Brilint tablets belong to the pharmacological group of medicines - antiaggregants and anticoagulants. The drug is used in the complex therapy of cardiovascular diseases, in which there is a high risk of blood clots in the blood vessels, which can lead to a cardiovascular catastrophe in the form of cerebral stroke or myocardial infarction.
Form of issue and composition
The drug form of the Brilint preparation is coated tablets. The main active substance of the drug is ticagrelor, the concentration of which in 1 tablet is 90 mg. Also the composition includes auxiliary substances:
- Calcium hydrogen phosphate is 63 mg.
- Mannitol - 126 mg.
- Carboxymethyl starch sodium - 9 mg.
- Magnesium stearate - 3 mg.
- Giprolase - 9 mg.
The composition of the coating covering the tablet includes such auxiliary substances:
- Titanium dioxide E 171 1.7 mg.
- Hypromellose 2910 - 5.6 mg.
- Talc 1.0 mg.
- Dye iron oxide yellow E172 - 0.1 mg.
- Macrogol 400 - 0.6 mg.
Tablets are packaged in 56 and 112 pieces. The cardboard pack also contains instructions for the use of the drug.
The main active substance of Brilint tablets is ticagrelyl (chemical class - cyclopentyltriazolopyrimidines). This selective and reversible P2Y protein antagonist acts on the adenosine diphosphate receptors, which prevents ADP-mediated activation and platelet binding (aggregation) and the formation of an intravascular thrombus. Thanks to this pharmacological action, Brilint's tablets prevent the formation of thrombi associated with the activation and aggregation of platelets.
After taking the pill inside the active substance of the drug is absorbed into the blood from the cavity of the small intestine. The therapeutic concentration in the blood is reached in 20-30 minutes after administration, the maximum concentration - after 1.5 hours. The active substance is evenly distributed in the tissues of the body, penetrates the blood-brain barrier into the brain tissue and through the placental barrier into the developing fetus and into milk during breastfeeding. Ticagreol is metabolized in the liver cells (hepatocytes), the products of its decay are excreted with bile. Half-life (the duration of excretion of half the dose of the drug taken from the body) is about 7 hours.
Indications for use
The reception of Brilint tablets is indicated for the reduction of blood clotting and the risk of developing cardiovascular complications in the form of thrombosis or thromboembolism in such diseases:
- Unstable angina - deterioration of blood circulation in the myocardium with a high risk of developing its infarction (death of the heart muscle when one of the arteries is blocked by a thrombus).
- Myocardial infarction - death of the site of the heart muscle (myocardium).
- Execution of surgical intervention on the coronary vessels of the heart - perekozhnoe coronary intervention (PCI) or aortocoronary bypass (AKV).
According to the doctor's prescription, the drug can be used to reduce the risk of developing thrombosis in other pathological conditions of the body, including DIC syndrome (disseminated intravascular coagulation).
Contraindications for use
The intake of Brilint tablets is contraindicated in certain pathological and physiological conditions of the body, which include:
- Individual intolerance or hypersensitivity to ticagreolol or ancillary components of the drug.
- The presence of active pathological bleeding.
- Hemorrhagic strokes (bleeding) of the brain, transferred in the past.
- Decrease in the functional activity of hepatocytes with the development of moderate or severe hepatic insufficiency.
- Concomitant administration of drugs that have a depressant effect on the enzyme CYP3A4 (clotrimazole, ketoconazole, clarithromycin, ritonavir, nefazodone and atazanavir).
- Children under 18 years of age - the absence of a negative effect of the drug on the children's body has not been reliably proven.
- Pregnancy at any time and breastfeeding, as there is a risk of adverse effects of the drug on the developing fetus.
In the absence of contraindications, you need to be sure before using Brilint tablets.
Dosing and Administration
Brilint tablets are taken inside whole, without chewing and regardless of food intake. After taking the pill, drink it with a sufficient amount of liquid. Dosage of the drug is 90 mg (1 tablet) per day, take the pill at the same time. Begin a course of treatment with a double dose (180 mg) on the first day, then switch to a constant intake of 90 mg. The average course of treatment is 12 months. It is necessary to take acetylsalicylic acid preparations in parallel with Brilint tablets as an additional antiaggregant. In case of missing the Brilint tablet, it is resumed on the next day at the usual reception time. It is necessary to avoid discontinuing the drug, as this can lead to a significant increase in the risk of developing thrombosis (the drug is canceled only by the doctor, in case of clinical necessity).
The main side effect of Brilint's tablets is excessive reduction in blood clotting with the development of various types of pathological bleeding - internal bleeding into the stroma or parenchyma of organs, post traumatic bleeding, development of bruising and bruising, especially after various intramuscular injections. Sometimes it is possible to develop an allergic reaction to ticagreol or auxiliary substances in the form of skin rash and itching. Rarely develops a more severe allergic reaction in the form of angioedema angioedema (characteristic rash and swelling of the skin, reminiscent of a nettle burn). It is also possible to develop anaphylactic shock (marked reduction in systemic blood pressure and multiple organ failure). On the part of the digestive system, nausea and vomiting are rarely noted. If there are side effects, the doctor decides to cancel the drug.
Before you start taking Brilint tablets, you should carefully read the instructions for the drug. During the use of tablets, special care should be taken with regard to trauma, as this can lead to severe bleeding. Also, while taking the drug, there is a high risk of bleeding after percutaneous coronary intervention or aortocoronary bypass surgery. The drug does not affect the concentration of attention or the speed of psychomotor reactions. Nevertheless, it is recommended to refuse to perform any activity related to the need for increased concentration of attention or speed of psychomotor reactions (work at altitude, driving a car or other transport). In pharmacies, the drug is dispensed only on prescription. In case of any questions or doubts about its reception, you should consult a doctor.
If the recommended therapeutic dose is exceeded, nausea, flatulence (accumulation of gases in the intestine), increases the risk of bleeding and disruption of the heart. In this case, gastric, intestinal and symptomatic washing is performed. There is no specific antidote to the active substance of the drug.
Analogues of Brilint tablets with respect to therapeutic effects are Clopidogrel, Aspigrel. A similar effect, but an excellent mechanism of action are drugs based on acetylsalicylic acid, used in cardiology as antiplatelet agents - Cardiomagnesium, Aspecard, Aspirin-Cardio.
Terms and conditions of storage
The shelf life of Brilint tablets is 2 years from the date of manufacture. Keep the drug in a dark, dry place at an air temperature of not more than + 30 ° C. Keep out of the reach of children.
Brilenty tablets 90mg, 56 pcs. - 4600-5300 rub.